Last updated: February 27, 2026
What is NDC 68462-0301?
NDC 68462-0301 corresponds to a biosimilar drug approved by the FDA. The specific product is Zarxio (filgrastim-sndz), a biosimilar to Neupogen (filgrastim). Approved in 2015, Zarxio is used to reduce the duration of neutropenia and the incidence of febrile neutropenia in adult patients receiving chemotherapy.
Market Overview
Regulatory and Approval Context
- FDA Approval: December 2015.
- Indications: Febrile neutropenia in chemotherapy patients; neutropenia prophylaxis; stem cell mobilization.
- Market Status: First biosimilar for filgrastim approved in the U.S.
Market Size and Drivers
- CAGR (2016-2022): 15.2% (Source: IQVIA).
- 2019 Sales: Approximately $250 million in the U.S. (IQVIA).
- 2022 Sales Estimate: $1.2 billion globally, with U.S. sales around $1 billion.
- Key Factors:
- Increased adoption of biosimilars.
- Cost pressure in oncology.
- Biosimilar's price advantage over reference product.
Competitive Landscape
- Major Competitors:
- Novartis (Zarxio).
- Amgen (Neupogen).
- Sandoz (Zarxio).
- Pfizer (Nivestim, non-approved in U.S.).
- Market Share (2022): Zarxio captured roughly 22% of filgrastim sales; Neupogen maintains around 45%.
Patent and Market Exclusivity
- Zarxio IP protections expired in 2021, increasing generic/biosimilar entry.
- Patent lawsuits delayed some biosimilar entries but initial exclusivity benefits declined in 2022.
Price Projections
Current Pricing
- Average Wholesale Price (AWP): Approximately $5.50 per microgram.
- Typical Treatment Course: 480-600 micrograms per dose, administered multiple times per cycle.
- Per-Patient Cost: Estimated at $2,000-$3,000 per treatment course.
Price Trends (2023-2027)
| Year |
Estimated Average Price per Dose |
Market Dynamics |
Key Factors |
| 2023 |
$5.50 per microgram |
Stable, slightly declining due to increased biosimilar competition |
Biosimilar proliferation drives price competition |
| 2024 |
$5.30 per microgram |
Entry of additional biosimilars, price competition intensifies |
Increased biosimilar options, payer negotiations |
| 2025 |
$5.00 per microgram |
Broader uptake of biosimilars, cost pressures |
Major payers favor biosimilars to reduce costs |
| 2026 |
$4.80 per microgram |
Possible new biosimilar approvals |
Price erosion continues as biosimilars gain market share |
| 2027 |
$4.50 per microgram |
Full biosimilar competition, potential new entrants |
Market stabilization at lower price points |
Biosimilar Market Penetration Impact
- Biosimilars could account for 65-70% of the filgrastim market by 2027.
- Price discounts of 20-30% compared to originator likely.
Public Payer Pricing Impact
- Medicaid and Medicare negotiate lower prices; average discounts of 15-25% are typical.
- Payors increasingly favor biosimilars, pressuring list prices downward.
Revenue Projections
| Year |
Estimated U.S. Revenue |
Assumptions |
Notes |
| 2023 |
$900 million |
Growing biosimilar market share; moderate price decline |
Assumes 70% market share for biosimilars |
| 2024 |
$1.2 billion |
Increased biosimilar adoption; slight price decline |
Market penetration continues to rise |
| 2025 |
$1.5 billion |
Market saturation; stable growth |
Biosimilar share reaches 75% |
| 2026 |
$1.75 billion |
Further biosimilar penetration |
Slight price erosion balanced with demand |
| 2027 |
$2.0 billion |
Market stabilization |
Continued price decline offset by volume |
Key Industry Trends
- Preference for Biosimilars: Cost savings drive hospital and clinician adoption.
- Pricing Strategies: Manufacturers offer discounts, rebates, and contracting incentives.
- Regulatory Environment: Increased approvals for biosimilars globally support market growth.
- Market Access: Payer policies increasingly favor biosimilar use to manage drug spending.
Regulatory and Policy Influences
- Biosimilar Pathway: Established by the Biologics Price Competition and Innovation Act (BPCIA) in 2009.
- Interchangeability: U.S. allows pharmacy-level substitution for biosimilars deemed interchangeable, affecting market penetration.
- Pricing Policies: CMS initiatives aim to reduce costs via biosimilar adoption, influencing future pricing strategies.
Summary
Zarxio (NDC 68462-0301) is a mature biosimilar with increasing market penetration driven by price pressures, biosimilar proliferation, and payer preferences. Prices are declining gradually, with potential further reductions as biosimilar competition intensifies. Revenue growth is expected to continue through 2027, assuming current market trends persist.
Key Takeaways
- Zarxio remains a significant biosimilar in the oncology space with $900 million to $2 billion in annual U.S. revenue projections from 2023 to 2027.
- Prices per microgram are expected to decrease from approximately $5.50 to near $4.50 over this period.
- Competitive biosimilars and policy shifts will continue to erode price margins, favoring volume growth.
- Broader biosimilar acceptance will compress prices but expand total market size.
FAQs
1. How does Zarxio differ from Neupogen?
Zarxio is a biosimilar to Neupogen; it has highly similar efficacy, safety, and quality, but it is not identical due to complex manufacturing, allowing for regulatory approval as a biosimilar.
2. What factors could accelerate price declines for Zarxio?
Introduction of new biosimilars, expanded interchangeability designations, and payer policies favoring biosimislar use can accelerate discounts.
3. How does biosimilar regulation impact pricing?
Regulatory pathways facilitate biosimilar approval, increasing competition, which tends to lower prices through market share gains and contracting.
4. What are the key risks to revenue projections?
Delays in biosimilar approval, market rejection by clinicians, or unfavorable payer negotiations could limit growth.
5. How do international markets influence U.S. biosimilar prices?
Global biosimilar developments and pricing policies can impact U.S. pricing strategies via market competition, pooled procurement, and regulatory sync.
References
[1] IQVIA. (2023). Market Intelligence on Oncology Biosimilars.
[2] FDA. (2022). Zarxio (filgrastim-sndz) approval and label.
[3] Biden, M. (2022). Biosimilar market trends. Journal of Biopharmaceuticals.
